Given successful early-phase clinical trials, pandemic-boosted manufacturing capabilities, and evidence of tumor-specific CD8+ T cell responses, the current generation of neoantigen-specific mRNA vaccines address some of the challenges that have historically limited the development of therapeutic cancer vaccines. The gene discussed is CD8A; the disease is neoplasm.